News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Jess Savala

Articles by Jess Savala

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

ByCharlotta Wadsten,Karuna Mittal,Pat W. Whitworth,Chirag Shah, MD,Frank Vicini, MD,Naamit Gerber,Melissa Krystel-Whittemore,Clayton C. Yates,Balasubramanyam Karanam,Walter Bell,Charles E. Cox, MS, FACS,Abigail Beard,Geza Acs,Steven C. Shivers,David J. Dabbs,Jess Savala,Mark Mentrikoski,Troy Bremer

April 14th 2025

104 Identification of Ductal Carcinoma In Situ Patients With Low-Risk Clinicopathology Who Benefit From Radiation Therapy With and Without Endocrine Therapy After Breast-Conserving Surgery Assessed With the 7-Gene Biosignature

ByPat W. Whitworth,Chirag Shah, MD,Frank Vicini, MD,Rachel Rabinovitch, MD,Julie A. Margenthaler, MD,Fredrik Warnberg,Micheal Leo,Sheila Weinmann,G. Bruce Mann,David J. Dabbs,Jess Savala,Steven C. Shivers,Karuna Mittal,Troy Bremer

April 12th 2025

39 7-Gene Predictive Biosignature Improves Risk Stratification for Breast Ductal Carcinoma In Situ Patients Compared to Clinicopathologic Criteria, Identifying a Low-Risk Group Not Clinically Benefiting from Adjuvant Radiotherapy

ByRachel Rabinovitch, MD,Frank A. Vicini, MD,Chirag Shah, MD,Julie A. Margenthaler, MD,Brian Czerniecki,Pat W. Whitworth,David J. Dabbs,G. Bruce Mann,Fredrik Wärnberg,Sheila Weinmann,Michael Leo,Jess Savala,Steven C. Shivers,Karuna Mittal,Troy Bremer

April 26th 2023

40 Characterization of Recurrence Risk After Lumpectomy and Radiotherapy in HER2-Positive Ductal Carcinoma in Situ of the Breast Using a 7-Gene Predictive Biosignature: Implications for the NSABP-B43 Trial Results

ByFrank A. Vicini, MD,Chirag Shah, MD,Rachel Rabinovitch, MD,Pat W. Whitworth,Julie A. Margenthaler, MD,Brian Czerniecki,David J. Dabbs,Sheila Weinmann,Michael Leo,G. Bruce Mann,Fredrik Wärnberg,Jess Savala,Steven C. Shivers,Karuna Mittal,Troy Bremer

April 26th 2023

Latest Updated Articles

Trending on CancerNetwork

Atirmociclib/Fulvestrant Improves PFS in HR+/HER2– Breast Cancer

Which Novel Drug Classes Hold Promise in Multiple Myeloma Therapy?

FDA Approves Companion Diagnostic for Niraparib in Advanced Ovarian Cancer

From Blunt Instruments to Molecular Precision: 40 Years of Oncology Evolution

NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium